Evidence map›Paper›PMID 40109466›Full record

ArticleSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2025

[Interpretation of the

Wenliang Lyu, Zhengmin Cao, Yong'an Ye, Lianjun Xing

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Wenliang Lyu（ 100053） Department of Hepatology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.
Zhengmin Cao（ 100053） Department of Hepatology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.
Yong'an Ye（ 100053） Department of Hepatology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.
Lianjun Xing（ 100053） Department of Hepatology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver cirrhosis is the terminal stage of various acute and chronic liver diseases and ranks 11th among the most common causes of death worldwide. In recent years, with the progress of clinical research, there has been increasing support from evidence-based medicine for the treatment of liver cirrhosis with integrated traditional Chinese and Western medicine. In 2023, the Chinese Association of Integrative Medicine, the China Association of Chinese Medicine, and the Chinese Medical Association jointly released the first evidence-based guideline in this field, the

Indexed as

Integrative MedicineLiver CirrhosisMedicine, Chinese TraditionalChinaDrugs, Chinese HerbalEvidence-Based MedicineHumansPractice Guidelines as TopicDrugs, Chinese HerbalIntegrative medicineInterpretation of the guidelinesLiver cirrhosis

Identifiers

PMID40109466
PMCPMC11914030

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.